Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLIVIA: Bevacizumab with mFOLFOX-6 or FOLFOXIRI in Colorectal Cancer
NCT00778102Phase 2
Key facts
- Status
- Completed
- Start
- Oct 2008
- Primary completion
- Oct 2013
- Countries
- 4
- Sponsor
- Roche
- Modality
- Monoclonal Antibodies
- Drugs
- bevacizumab
- Conditions
- colorectal cancer (CRC)
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in colorectal cancer (CRC) (2 arms), sponsored by Roche. Primary endpoint: Percentage of Participants With Complete Resection or Residual (Microscopic or Macroscopic) Tumor up to 5 years. Started Oct 2008; status: completed.
02
Design
2 arms- Study design
- RandomizedOpen-label
mFOLFOX-6 + Bevacizumab
5-FU, Leucovorin, Oxaliplatin, Bevacizumab
FOLFOXIRI + Bevacizumab
5-FU, Leucovorin, Oxaliplatin, Irinotecan, Bevacizumab
03
Who it enrols
Adult patients with unresectable liver metastasis secondary to colorectal cancer, ECOG 0-1, and no prior systemic treatment for metastatic disease.
04
Endpoints
Primary
Percentage of Participants With Complete Resection or Residual (Microscopic or Macroscopic) Tumor
Secondary
Time to Resection
Percentage of Participants With Histopathological Response
Percentage of Participants With Complete or Major Histopathological Response
Percentage of Participants Experiencing Relapse Following Curative Resection
Relapse-Free Survival
Progression-Free Survival
Overall Survival
Percentage of Participants With a Confirmed Best Overall Response of Complete Response (CR) or Partial Response (PR) According to RECIST Version 1.0
05
Results
Not all primary endpoints met
Beyond the preview
Go deeper on NCT00778102.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00778102.